Novartis ends mid-stage Fabhalta trial in lupus nephritis citing strategic considerations

Novartis has terminated its mid-stage trial of Fabhalta (iptacopan) in patients with lupus nephritis, according to a federal clinical trials registry.

The company said the decision was driven by strategic considerations, not by safety or efficacy concerns disclosed in the public record.

Fabhalta remains a key asset in Novartis' pipeline, and the termination may affect the company's portfolio strategy and investor outlook.